Volume 2 / Issue 3
We are excited to present the 2014 Summer/Autumn Oncotype DX® Breast Cancer Assay newsletter, bringing you news and information from Genomic Health®, to keep you well informed and help you manage your patients with early-stage invasive breast cancer and ductal carcinoma in situ (DCIS).
At the 2014 ASCO® annual meeting earlier this year, Dr. Michael Alvarado, Director of Breast Surgery Oncology Fellowship at the University of California, presented a study (Prasad et al. ASCO® 2014) that compares the Oncotype DX® Breast Cancer Assay (21-gene assay) and the Prosigna™ Score based on the PAM50 ROR assay. The study shows that there is poor correlation between the Recurrence Score® results and the Prosigna ROR results in Node-negative patients.
This newest study adds to the growing body of evidence that not all assays are the same and cannot be used interchangeably. Previous studies (Denduluri et al. ASCO® Breast 2011; Clough et al. SABCS 2012; Shivers et al. SABCS 2013; Dowsett et al. J Clin Oncol. 2013) have shown that patients are classified differently by different assays and misclassification can potentially increase the risk of over- or under-treatment. Order the one assay that is both prognostic and predictive of adjuvant therapy benefit, included in major clinical guidelines and validated in six separate studies, the Oncotype DX® Breast Cancer Assay.
Watch a video of Dr. Alvarado discussing the study.
Also at the 2014 ASCO® annual meeting, Dr. Alvarado, presented a poster with positive data regarding the clinical utility of the
Oncotype DX® DCIS Score™ result. After 115 patients were analyzed, the results of this study showed that integration of the
DCIS Score™ result changed treatment recommendations 31% of the time.
Watch Dr. Alvarado discuss this DCIS study.
<strong>Spotlight On...Breast Cancer Awareness Month</strong>
<strong>Don’t Be Afraid to Be Your Own Advocate: A DCIS Patient Story - Amy T.</strong>
<strong>The DCIS Score Result: Potential for Health Care Savings? </strong>
<strong>Does Tumor Size Matter?</strong>
<strong>Not All Breast Cancer Assays Are the Same…A Review of Commercially Available Genomic Profilers</strong>
<strong>Looking Forward to Seeing You at the 2014 San Antonio Breast Cancer Symposium</strong>
We join the community of breast cancer patients, survivors, healthcare providers, caregivers, families and friends in commemorating National Breast Cancer Awareness Month. In honor of Breast Cancer Awareness Month, we are featuring the recently redesigned MyBreastCancerTreatment.org website – a valuable resource for your patients.
"Everyone should have the knowledge and ability to ask their doctor if Oncotype DX® is right for them. We have a right to decide what breast cancer treatment is right for us. Don’t be afraid to be your own advocate."
Copyright © 2004-2017 Genomic Health, Inc. All Rights Reserved.
The content on this site is intended for U.S. patients and caregivers only.